Investment Research and Business Due Diligence
Thursday, August 1, 2013
Vivimed Acquires A US FDA Approved Formulation Manufacturing Facility
Vivimed Labs Ltd., manufacturer of specialty chemicals and pharmaceuticals,
the signing of an agreement to acquire Actavis Pharma Manufacturing Pvt. Ltd.'s solid oral dosage facility in Alathur in Tamil Nadu for an aggregate consideration of Rs.122 crore.
The facility is being acquired from its parent Actavis Holding Asia B.V., an
of Actavis Inc., a leading global general and specialty pharmaceutical company.
This acquisition is strategically attractive given it provides Vivimed with immediate finished dosage formulations access to the US, the largest generics market in the world. In addition, this US FDA approved facility is a natural extension for Vivimed's manufacturing platform which currently only caters to the FEF semi-regulated
Commence on these developments, Managing Director and CEO Santosh Varalwar said, "This acquisition is particularly important given it provides our finished dosage formulation manufacturing platform with a US FDA approved facility and immediate access the regulated markets. There are also compelling forward integration synergies for Vivimed's existing API
and formulations dossier development activities. Along with the facility, we have acquired to commercially valuable and marketable ANDAs which we believe, will allow us to generate additional revenues. We re also entering into a
manufacturing agreement with the Actavis Group for a defined period which will also be a source of revenue for us. The transaction has been
attractively at a low
consideration for Vivimed."
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)